{"id":"https://openalex.org/W3029402008","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3165","title":"A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).","display_name":"A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3029402008","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3165","mag":"3029402008"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.tps3165","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3165","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3165","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077579849","display_name":"George R. Blumenschein","orcid":"https://orcid.org/0000-0002-9606-8194","observed_orcids":["https://orcid.org/0000-0002-9606-8194"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George R. Blumenschein","raw_affiliation_strings":["Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030169825","display_name":"Diwakar Davar","orcid":"https://orcid.org/0000-0002-7846-8055","observed_orcids":["https://orcid.org/0000-0002-7846-8055"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diwakar Davar","raw_affiliation_strings":["University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112841365","display_name":"Rodolfo Gutierrez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210104507","display_name":"Angeles Clinic and Research Institute","ror":"https://ror.org/01ct2ab72","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodolfo Gutierrez","raw_affiliation_strings":["The Angeles Clinic & Research Institute, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Angeles Clinic & Research Institute, Los Angeles, CA;","institution_ids":["https://openalex.org/I4210104507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062202820","display_name":"Neil Howard Segal","orcid":"https://orcid.org/0000-0002-3047-2303","observed_orcids":["https://orcid.org/0000-0002-3047-2303"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil Howard Segal","raw_affiliation_strings":["Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY;","institution_ids":["https://openalex.org/I1334819555","https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049294543","display_name":"Melissa Lynne Johnson","orcid":"https://orcid.org/0000-0001-9874-1314","observed_orcids":["https://orcid.org/0000-0001-9874-1314"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Lynne Johnson","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110684921","display_name":"Mohammed M. Dar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mohammed M. Dar","raw_affiliation_strings":["Immunocore Ltd, Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immunocore Ltd, Rockville, MD;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111635921","display_name":"Shannon A. Marshall","orcid":"https://orcid.org/0009-0007-2148-2490","observed_orcids":["https://orcid.org/0009-0007-2148-2490"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shannon Marshall","raw_affiliation_strings":["Immunocore Ltd, Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immunocore Ltd, Rockville, MD;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"TPS3165","last_page":"TPS3165"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8720999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8720999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.11209999769926071,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immtac","display_name":"ImmTAC","score":0.7379999756813049},{"id":"https://openalex.org/keywords/mage-a4","display_name":"MAGE-A4","score":0.9890000224113464},{"id":"https://openalex.org/keywords/cancer-testis-antigens","display_name":"cancer-testis antigens","score":0.8420000076293945},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9490000009536743},{"id":"https://openalex.org/keywords/hla-a-0201","display_name":"HLA-A*0201","score":0.9610000252723694},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8080000281333923},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7170000076293945},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.503000020980835},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6819999814033508},{"id":"https://openalex.org/keywords/t-cell-redirection","display_name":"T cell redirection","score":0.6150000095367432},{"id":"https://openalex.org/keywords/tebentafusp","display_name":"tebentafusp","score":0.7350000143051147},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7110000252723694},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.734000027179718}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.704344630241394},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.6190915107727051},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.59477698802948},{"id":"https://openalex.org/C19317047","wikidata":"https://www.wikidata.org/wiki/Q412037","display_name":"T-cell receptor","level":4,"score":0.5585106611251831},{"id":"https://openalex.org/C114684123","wikidata":"https://www.wikidata.org/wiki/Q419458","display_name":"CD3","level":4,"score":0.5447869896888733},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4900723695755005},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.48032107949256897},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.46802836656570435},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.4556782841682434},{"id":"https://openalex.org/C188280979","wikidata":"https://www.wikidata.org/wiki/Q911125","display_name":"Human leukocyte antigen","level":3,"score":0.429744154214859},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4183613061904907},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.417776882648468},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.38683268427848816},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33101582527160645},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.281463086605072},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.26429495215415955},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.20344328880310059},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.13809162378311157},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.12237608432769775}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.tps3165","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3165","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps3165","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7169805327","https://openalex.org/W4311146651","https://openalex.org/W4200370560","https://openalex.org/W2977825834","https://openalex.org/W2043288748","https://openalex.org/W1506051993","https://openalex.org/W7162937651","https://openalex.org/W1537165791","https://openalex.org/W7162578002","https://openalex.org/W4295819131"],"abstract_inverted_index":{"TPS3165":[0],"Background:":[1],"ImmTAC":[2,34,69,89,122],"bispecifics":[3],"are":[4,13,29,211,218],"unique":[5],"T":[6,18,72,84],"cell":[7,73],"receptor":[8],"(TCR)/anti-CD3":[9],"bispecific":[10],"molecules":[11,35,46,70],"that":[12],"designed":[14],"to":[15,25,31,64,110,199,219],"redirect":[16,71],"polyclonal":[17],"cells":[19],"against":[20,75,92,128],"intracellular":[21],"antigens,":[22],"in":[23,104,123,137,153,177,203,248],"contrast":[24],"antibody-based":[26],"therapies,":[27],"which":[28,94],"limited":[30],"extracellular":[32],"antigens.":[33],"recognize":[36],"a":[37,162],"specific":[38,197],"peptide":[39],"presented":[40],"on":[41,113],"defined":[42,204],"Class":[43],"I":[44],"HLA":[45],"via":[47],"an":[48,58,88,229],"affinity":[49],"enhanced,":[50],"engineered,":[51],"soluble":[52],"TCR.":[53],"Through":[54],"the":[55,65,80,83,97,221],"addition":[56],"of":[57,79,82,169,215,231],"anti-CD3":[59],"scFv":[60],"effector":[61],"domain":[62],"fused":[63],"TCR":[66],"targeting":[67],"domain,":[68],"activity":[74,136],"cancer":[76,101],"cells,":[77],"regardless":[78],"specificity":[81],"cell.":[85],"IMC-C103C":[86,170,187,243],"is":[87,95,149,161,247],"being":[90,150],"investigated":[91],"MAGE-A4,":[93],"among":[96],"most":[98,120],"commonly":[99],"expressed":[100],"testis":[102],"antigens":[103],"solid":[105],"malignancies,":[106],"but":[107],"with":[108,155,175,180,209],"minimal":[109],"absent":[111],"expression":[112],"normal":[114],"tissues":[115],"and/or":[116],"hematopoietic":[117],"cells.":[118],"The":[119,184],"advanced":[121,143,182],"development,":[124],"tebentafusp":[125],"(IMCgp100),":[126],"directed":[127],"melanocyte-associated":[129],"lineage":[130],"antigen":[131],"gp100,":[132],"has":[133],"shown":[134],"monotherapy":[135,172,188,244],"uveal":[138,146],"melanoma":[139],"and":[140,145,157,173,223,241],"PD-1":[141],"refractory":[142],"cutaneous":[144],"melanoma.":[147],"Tebentafusp":[148],"further":[151],"evaluated":[152],"combination":[154,174],"durvalumab":[156],"tremelimumab.":[158],"Methods:":[159],"IMC-C103C-101":[160],"multi-center,":[163],"open-label,":[164],"Phase":[165],"1/2":[166],"first-in-human":[167],"study":[168,185],"as":[171],"atezolizumab":[176,210],"HLA-A*02:01-positive":[178],"patients":[179],"MAGE-A4-positive":[181],"cancers.":[183],"includes":[186],"(Q1W)":[189],"dose":[190,216,245],"escalation,":[191],"followed":[192],"by":[193,236],"expansion":[194],"into":[195],"indication":[196],"arms":[198],"test":[200],"for":[201],"efficacy":[202,232],"patient":[205],"cohorts.":[206],"Concurrently,":[207],"combinations":[208],"planned.":[212],"Primary":[213],"objectives":[214,227],"escalation":[217,246],"identify":[220],"MTD/RP2D,":[222],"characterize":[224],"safety/tolerability.":[225],"Secondary":[226],"include":[228],"assessment":[230],"(best":[233],"overall":[234],"response":[235],"RECIST":[237],"v1.1),":[238],"PK,":[239],"PD,":[240],"ADA.":[242],"progress.":[249],"Clinical":[250],"trial":[251],"information:":[252],"NCT03973333":[253],".":[254]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-06-05T00:00:00"}